Sarepta Therapeutics recently joined C3 to present a community webinar titled “Journey Update for the LGMD2A/R1 Calpainopathy Community.” During the webinar, Sarepta discussed the essential role for natural history studies throughout the drug development process. They then shared the design
Volker Straub appointed to C3 Scientific Advisory Board
Coalition to Cure Calpain 3 (C3) is pleased to share that Dr. Volker Straub has been appointed to our Scientific Advisory Board (SAB), joining Dr. Melissa Spencer (Chair), Dr. Kevin Campbell, Dr. Eric Hoffman, and Dr. Louis Kunkel. Professor Volker
C3 hosts Sarepta to present webinar about the JOURNEY natural history study
Click here to register!
C3 attends the 2024 MDA Clinical and Scientific Conference
The Muscular Dystrophy Association held their 2024 Clinical and Scientific Conference on March 3-6 in Orlando, Florida. C3 Scientific Director Dr. Jennifer Levy attended the meeting and shares the following highlights: The MDA Public Policy and Advocacy Team convened representatives
Trial readiness study for individuals with LGMD2A/R1
Please contact either Ruby Langeslay or Jennifer Raymond at Virginia Commonwealth University for more information
KNOW YOUR CODE: Why the new ICD-10 codes matter, and what you can do to confirm your records
Did you know that new ICD-10 codes were assigned for limb-girdle muscular dystrophies (LGMDs) in October 2022? Patients with LGMD2A/R1, autosomal recessive LGMD due to Calpain 3-dysfunction, have been given a diagnosis code of G71.032. Patients with LGMD1i/D4, autosomal dominant
Countdown to the New Year – 2023 Edition
This year, C3 collaborated with 5 other LGMD organizations to publish the Voice of the Patient Report, summarizing the 2022 Externally-Led Patient Focused Drug Development Meeting and highlighting the unmet medical needs of the LGMD community. READ MORE Connected with
New LGMD2A/R1 mouse model available at Jackson Labs
Coalition to Cure Calpain 3 (C3) is pleased to share that a new Calpain 3-null mouse strain is available through the Jackson Labs repository. This line is crossed onto an NSG background, resulting in an immunodeficient strain. The NSG.Capn3 KO mice may
Genetic testing for LGMDs
Limb-girdle muscular dystrophies (LGMDs) were characterized in the clinic before anyone knew what caused the diseases. Consequently, several different diseases that all looked the same to physicians were lumped together into one category that they called “LGMD.” As science advanced,
Dr. Stephanie Hunn awarded C3 Travel Grant
Coalition to Cure Calpain 3 (C3) is pleased to announce that Stephanie Hunn DPT was awarded a Travel Grant for the presentation of her research at the Annual Congress of the World Muscle Society in Charleston, South Carolina, from October